NTRK3 and melanoma: For STK, one peptide (derived from FKBP12-rapamycin complex-associated protein, (FRAP), aka Mammalian target of rapamycin (mTOR)) contains the AKT phosphorylation site of mTOR, the other is a Protein Kinase C (PKC)-derived peptide and the third is derived from the Neurotrophic tyrosine kinase receptor type 3 (NTRK3) (involved in several cancers, e.g., melanoma) [33].